On 2 June 2010, the Registry was assigned an additional statutory mission. It consists of collecting all anatomopathological test results as part of the early detection programme for cancer and creating a central cyto-histopathology registry. In specific terms this means that all results of cervical, breast and colon samples must be registered, regardless of the diagnosis. This central cyto-histopathology registry will also contain the results of normal and minor abnormal samples as well as the typical cancer diagnoses. Specific guidelines for registering test results as part of the early detection programme for cancer can be downloaded here.

Prior to the launch of this central registry, the Belgian Cancer Registry organised for a feasibility study to be carried out that focused on cervical cancer. This study resulted in CERVIBASE, a registry for all cervical samples. You can find more information on the relative pages for cervical cancer or in our newsletter of January 2011.


The extra mission is an offshoot of the 2003 European Union recommendation for screening programmes for cervical cancer, breast and colorectal cancer. An effective cyto-histopathology registry containing anatomopathological test results is crucial for guaranteeing the effectiveness, efficiency and quality of these screening programmes. A central registry also allows quality indicators to be monitored. 

Moreover a central cyto-histopathology registry is necessary for establishing fail-safe screening in accordance with the guidelines. A fail-safe mechanism must be used to guarantee that each patient with an abnormal screening result receives the necessary medical follow-up.
The pathologists now register the data for the diagnosis as well as for the early detection programme for cancer and supply them to the Belgian Cancer Registry in different data sets. The complete manual for this procedure can be downloaded here.